Mangrove Partners Chemo Centryx, Inc. Transaction History

Mangrove Partners

$769 Million
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $883,778 - $1.56 Million	-39,774 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $731,046 - $1.61 Million	39,774 New	39,774 $1.45 Million
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $16.7 Million - $23 Million	-353,219 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $9.69 Million - $12.9 Million	209,104 Added 145.1%	353,219 $19.4 Million
Q2 2020 Aug 14, 2020	SELL	$38.58 - $65.07 $17.1 Million - $28.8 Million	-442,408 Reduced 75.43%	144,115 $8.29 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $19.2 Million - $29.8 Million	586,523 New	586,523 $23.6 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

News

Stay updated on Mangrove Partners with notifications on news.